Biotech Symposium: Innovations in Regenerative Medicine

CBSA's annual Biotech Symposium brings together the state's biotech leaders to discuss recent developments and new trends in the community. The event will include a keynote speaker, exhibitor booths, panel discussions, and networking opportunities.

Navigating the Changing ATMP Market: A Conversation on the Future of Cell and Gene

Mark Landolt

Manufacturing Manager, Cell Therapy

AGC Biologics

Mark Landolt, Manufacturing Manager – Cell Therapy, has over 12 years of pharmaceutical manufacturing experience within the mammalian, radioactive pharma, and cell & gene spaces. Currently the Cell Therapy Manufacturing Manager with AGC Biologics for the last two and half years."

Raghu Malapaka, Ph.D.

Senior Director, Global BD, Cell and Gene Therapy

AGC Biologics

Dr. Raghu Malapaka has an extensive background in the development and manufacturing of large molecules as well as advanced therapies. His role as Senior Director for Global Business Development at AGC Biologics highlights his expertise in steering the growth and expansion of cell and gene therapy manufacturing services. Dr. Malapaka has a solid foundation with a PhD molecular biology and post-doctoral work at Harvard Medical School. His career

trajectory through prominent companies like Thermofisher Scientific, Kaneka, and WuXi Biologics reflects a consistent upward momentum and a commitment to excellence in the field of biologics.

Marissa Rodrigues

Senior Manager, Quality Control

AGC Biologics

Marissa Rodrigues, Senior Manager Quality Control, brings over a decade of Quality Control and Quality Assurance experience in FDA regulated industries. Marissa has a Master's degree in Microbiology from the University of Mumbai, India and a Master's degree from the University of Tennessee where she researched the virulence mechanisms of pathogenic yeasts. Marissa began her career in clinical and diagnostic microbiology in hospital settings before progressing into various quality roles in Microbiology, Quality Engineering, and Quality Assurance within pharmaceutical and biotechnology companies.

Marissa has experience with a wide niche of complex pharmaceuticals from development to product launch and has experience collaborating with academic institutions, government health entities, large pharmaceutical corporations, and start-up companies to achieve crucial milestones throughout their research and therapeutic pipelines. In her current role she leads all aspects of QC new product on-boarding for large-scale commercial phase biologics and cell and gene therapy clients at various stages of development and commercialization

Jeff Rosenbloom

Director of MSAT Cell and Gene Therapies

AGC Biologics

Jeff Rosenbloom, Director of MSAT Cell and Gene Therapies, received his Bachelor's degree in Integrated Biology from the University of Florida, and a Master's degree in Bioprocessing from the Keck Graduate Institute of Applied Life Sciences. In his career, he has experiences working with multiple modalities, including mammalian/biologics production, diagnostics, as well as in modified and un-modified cell and gene therapies.

During Jeff's career, he has worked for innovator companies, contract research organizations, as well as CDMO's, specializing in MSAT, process development, and analytical development for clients at various stages of development and commercialization. He has experience implementing and driving cell therapy programs from early phase clinical manufacturing through inspection and into commercial applications.

Whitney Sandberg

SVP and General Manager

AGC Biologics

Whitney Sandberg is a seasoned leader in the biopharmaceutical industry, currently serving as the General Manager of AGC Biologics in Longmont and Boulder, Colorado. With nearly three decades of experience, she brings a wealth of expertise to her role, overseeing both mammalian and cell and gene therapy production.

Throughout her career, Whitney has held key leadership positions at prominent organizations, including Wyeth-Biopharma (now Pfizer) and Bristol Myers Squibb. In these roles, she demonstrated her exceptional leadership skills by guiding teams through the complexities of clinical and commercial manufacturing, delivering high-quality products to market.

Before joining AGC Biologics, Whitney served as the head of Global Quality for the Biologics business unit within ThermoFisher Scientific's Pharma-Services Group. In this capacity, she played a pivotal role in ensuring the highest standards of quality and compliance across the organization.

Mike Swabowski

Vice President of Quality

AGC Biologics

Mike Swabowski, Vice President of Quality, brings over two decades of experience in FDA regulated industries to his role. Mike has a Bachelor's

degree in biology from the University of Illinois Chicago and multiple certifications from the American Society for Quality. Mike's career journey is marked by a 20-year tenure dedicated to various Quality roles and four years leading Manufacturing and Logistics teams.

Mike has worked on multiple regulated products within the clinical and commercial space spanning the industries of Medical Devices, Radiopharmaceuticals, Sterile Parenterals/Intrathecals, Biologics and Cell and Gene Therapy. Mike has worked at innovator companies and CDMOs, in both site and corporate level roles, and has experience in implementing Phase Appropriate Quality Systems and Integrating Products in Quality Systems.